The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition

被引:123
作者
Scherma, Maria [1 ,2 ]
Medalie, Julie [1 ]
Fratta, Walter [2 ]
Vadivel, Subramanian K. [3 ]
Makriyannis, Alexandros [3 ]
Piomelli, Daniele [4 ]
Mikics, Eva [5 ]
Haller, Jozsef [5 ]
Yasar, Sevil [6 ]
Tanda, Gianluigi [7 ]
Goldberg, Steven R. [1 ]
机构
[1] NIDA, Preclin Pharmacol Sect, Behav Neurosci Res Branch, Intramural Res Program,NIH,DHHS, Baltimore, MD USA
[2] Univ Cagliari, Bb Brodie Dept Neurosci, I-09124 Cagliari, Italy
[3] Northeastern Univ, Ctr Drug Discovery, Boston, MA 02115 USA
[4] Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA
[5] Hungarian Acad Sci, Inst Expt Med, Budapest, Hungary
[6] Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA
[7] Natl Inst Drug Abuse, Psychobiol Sect, Med Discovery Res Branch, Intramural Res Program,NIH,Dept Hlth & Human Serv, Baltimore, MD 21224 USA
关键词
endogenous cannabinoids; anandamide; FAAH; URB597; WIN 55,212-2; conditioned place preferences; anxiety; locomotor activity; rats;
D O I
10.1016/j.neuropharm.2007.08.011
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Converging evidence suggests that the endocannabinoid. system is an important constituent of neuronal substrates involved in brain reward processes and emotional responses to stress. Here, we evaluated motivational effects of intravenously administered anandamide, an endogenous ligand for cannabinoid CB1-receptors, in Sprague-Dawley rats, using a place-conditioning procedure in which drugs abused by humans generally produce conditioned place preferences (reward). Anandamide (0.03-3 mg/kg intravenous) produced neither conditioned place preferences nor aversions. However, when rats were pre-treated with the fatty acid amide hydrolase (FAAH) inhibitor URB597 (cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester; 0.3 mg/kg intraperitoneal), which blocks anandamide's metabolic degradation, anandamide produced dose-related conditioned place aversions. In contrast, URB597 alone showed no motivational effects. Like URB597 plus anandamide, the synthetic CB1-receptor ligand WIN 55,212-2 (50-300 mu g/kg, intravenous) produced dose-related conditioned place aversions. When anxiety-related effects of anandamide and URB597 were evaluated in a light/dark box, both a low anandamide dose (0.3 mg/kg) and URB597 (0.1 and 0.3 mg/kg) produced anxiolytic effects when given alone, but produced anxiogenic effects when combined. A higher dose of anandamide (3 mg/kg) produced anxiogenic effects and depressed locomotor activity when given alone and these effects were potentiated after URB597 treatment. Finally, anxiogenic effects of anandamide plus URB597 and development of place aversions with URB597 plus anandamide were prevented by the CBI-receptor antagonist AM251 (3 mg/kg intraperitoneal). Thus, additive interactions between the effects of anandamide on brain reward processes and on anxiety may account for its aversive effects when intravenously administered during FAAH inhibition with URB597. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:129 / 140
页数:12
相关论文
共 47 条
[1]   Functional role of high-affinity anandamide transport, as revealed by selective inhibition [J].
Beltramo, M ;
Stella, N ;
Calignano, A ;
Lin, SY ;
Makriyannis, A ;
Piomelli, D .
SCIENCE, 1997, 277 (5329) :1094-1097
[2]   Anxiolytic-like properties of the anandamide transport inhibitor AM404 [J].
Bortolato, Marco ;
Campolongo, Patrizia ;
Mangieri, Regina Anne ;
Scattoni, Maria Luisa ;
Frau, Roberto ;
Trezza, Viviana ;
La Rana, Giovanna ;
Russo, Roberto ;
Calignano, Antonio ;
Gessa, Gian Luigi ;
Cuomo, Vincenzo ;
Piomelli, Daniele .
NEUROPSYCHOPHARMACOLOGY, 2006, 31 (12) :2652-2659
[3]   LOCOMOTOR AND REWARDING EFFECTS OF AMPHETAMINE IN ENRICHED, SOCIAL, AND ISOLATE REARED RATS [J].
BOWLING, SL ;
BARDO, MT .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1994, 48 (02) :459-464
[4]   Δ9-Tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats [J].
Braida, D ;
Iosuè, S ;
Pegorini, S ;
Sala, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 506 (01) :63-69
[5]   5-HT1A receptors are involved in the anxiolytic effect of Δ9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats [J].
Braida, Daniela ;
Limonta, Valeria ;
Malabarba, Lorenzo ;
Zani, Alessia ;
Sala, Mariaelvina .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 555 (2-3) :156-163
[6]   Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats [J].
Chaperon, F ;
Soubrié, P ;
Puech, AJ ;
Thiébot, MH .
PSYCHOPHARMACOLOGY, 1998, 135 (04) :324-332
[7]   PRELIMINARY-REPORT OF A SIMPLE ANIMAL BEHAVIOR MODEL FOR THE ANXIOLYTIC EFFECTS OF BENZODIAZEPINES [J].
CRAWLEY, J ;
GOODWIN, FK .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1980, 13 (02) :167-170
[8]   Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats [J].
Deiana, Serena ;
Fattore, Liana ;
Spano, M. Sabrina ;
Cossu, Gregorio ;
Porcu, Emanuele ;
Fadda, Paola ;
Fratta, Walter .
NEUROPHARMACOLOGY, 2007, 52 (02) :646-654
[9]   ISOLATION AND STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR [J].
DEVANE, WA ;
HANUS, L ;
BREUER, A ;
PERTWEE, RG ;
STEVENSON, LA ;
GRIFFIN, G ;
GIBSON, D ;
MANDELBAUM, A ;
ETINGER, A ;
MECHOULAM, R .
SCIENCE, 1992, 258 (5090) :1946-1949
[10]   Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats [J].
Fattore, L ;
Cossu, G ;
Martellotta, CM ;
Fratta, W .
PSYCHOPHARMACOLOGY, 2001, 156 (04) :410-416